Unlocking the potential of gene therapy for patients with rare and orphan diseases

About Medgenics

At Medgenics, we share one singular focus - to transform the lives of our patients through the development of innovative and best-in-class therapies. We are dedicated to developing our unique technology platform (TARGT) for the express purpose of treating patients with rare and orphan diseases.


TARGT has demonstrated several advantages over current gene or protein therapy, including efficacy, safety and capital efficiency.

Latest News

07-15-15 Medgenics Announces First Patient Enrolled in U.S.-Based Phase 2 Clinical Trial of TARGT-EPO for Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis 06-29-15 Medgenics Added to RUSSELL 3000(R) and Global Indexes 06-17-15 Medgenics to Present at JMP Securities Life Sciences Conference 2015